Browsing "Medicine" by Title

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1430 to 1449 of 12299 < previous   next >
PreviewIssue DateTitleAuthor(s)
2012C-IBS patients lack monocyte derived β-endorphin which results in disinhibition of colonic afferent mechanosensitivityHughes, P.; Nicholson, I.; Bird, D.; To, S.; Isaacs, N.; Grasby, D.; Persson, J.; Harrington, A.; Brierley, S.; Zola, H.; Andrews, J.; Blackshaw, L.; Krumbiegel, D.; Digestive Disease Week (2012 : San Diego, California)
1998The c-Myb oncoproteinGonda, T.
2002C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight lossHeilbronn, L.; Clifton, P.
2017C-Reactive Protein as a Marker of Inflammation in Acute Psychosis and SchizophreniaWeickert, T.; Jacomb, I.; Stanton, C.; Vasudevan, R.; Powell, H.; Liu, D.; Galletly, C.; Lenroot, R.; O'Donnell, M.; Weickert, C.; 72nd Annual Scientific Convention and Meeting of the Society of Biological Psychiatry (SOBP 2017) (18 May 2017 - 20 May 2017 : San Diego, CA)
2007C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndromeMoran, L.; Noakes, M.; Clifton, P.; Wittert, G.; Belobrajdic, D.; Norman, R.
2013C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapyPuri, R.; Nissen, S.; Libby, P.; Shao, M.; Ballantyne, C.; Barter, P.; Chapman, M.; Erbel, R.; Raichlen, J.; Uno, K.; Kataoka, Y.; Nicholls, S.
2012C-reactive protein, fibrinogen, and cardiovascular disease predictionKaptoge, S.; Di Angelantonio, E.; Pennells, L.; Wood, A.; White, I.; Gao, P.; Walker, M.; Thompson, A.; Sarwar, N.; Caslake, M.; Butterworth, A.; Amouyel, P.; Assmann, G.; Bakker, S.; Barr, E.; Barrett-Connor, E.; Benjamin, E.; Björkelund, C.; Brenner, H.; Brunner, E.; et al.
2010The c-Rel subunit of nuclear factor-κB regulates murine liver inflammation, wound-healing, and hepatocyte proliferationGieling, R.; Elsharkawy, A.; Caamano, J.; Cowie, D.; Wright, M.; Ebrahimkhani, M.; Burt, A.; Mann, J.; Raychaudhuri, P.; Liou, H.; Oakley, F.; Mann, D.
2010The C282Y polymorphism of the hereditary hemochromatosis gene is associated with increased sex hormone-binding globulin and normal testosterone levels in menYeap, B.; Beilin, J.; Shi, Z.; Knuiman, M.; Olynyk, J.; Chubb, S.; Bruce, D.; Milward, E.
2015C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodiesFuss, A.; Hope, C.; Deayton, S.; Bennett, G.; Holdsworth, R.; Carroll, R.; Coates, P.
2014Cable monitoring solution - predict with certaintySingh, K.; IET International Conference on Developments in Power System Protection (DPSP) (31 Mar 2014 - 03 Apr 2014 : Copenhagen, Denmark)
2014Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studySmith, M.; Sweeney, C.; Corn, P.; Rathkopf, D.; Smith, D.; Hussain, M.; George, D.; Higano, C.; Harzstark, A.; Sartor, A.; Vogelzang, N.; Gordon, M.; De Bono, J.; Haas, N.; Logothetis, C.; Elfiky, A.; Scheffold, C.; Laird, A.; Schimmoller, F.; Basch, E.; et al.
2013Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialSmith, D.; Smith, M.; Sweeney, C.; Elfiky, A.; Logothetis, C.; Corn, P.; Vogelzang, N.; Small, E.; Harzstark, A.; Gordon, M.; Vaishampayan, U.; Haas, N.; Spira, A.; Lara, P.; Lin, C.; Srinivas, S.; Sella, A.; Schöffski, P.; Scheffold, C.; Weitzman, A.; et al.
2015Cabozantinib inhibits abiraterone's upregulation of IGFIR phosphorylation and enhances its anti-prostate cancer activityWang, X.; Huang, Y.; Christie, A.; Bowden, M.; Lee, G.; Kantoff, P.; Sweeney, C.
2008Cachexia and neuropeptide YMorley, J.; Farr, S.
2013Cachexia as a major public health problem: frequent, costly and deadlyFarkas, J.; von Haehling, S.; Kalantar-Zadeh, K.; Morley, J.; Anker, S.; Lainscak, M.
2008Cachexia: a new definitionEvans, W.; Morley, J.; Argiles, J.; Bales, C.; Baracos, V.; Guttridge, D.; Jatoi, A.; Kalantar-Zadeh, K.; Lochs, H.; Mantovani, G.; Marks, D.; Mitch, W.; Muscaritoli, M.; Najand, A.; Ponikowski, P.; Fanelli, F.; Schambelan, M.; Schols, A.; Schuster, M.; Thomas, D.; et al.
2019Caesarean section and risk of type 1 diabetes: whole-of-population studyBegum, M.; Pilkington, R.; Chittleborough, C.; Lynch, J.; Penno, M.; Smithers, L.
2019CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecanVennin, C.; Mélénec, P.; Rouet, R.; Nobis, M.; Cazet, A.; Murphy, K.; Herrmann, D.; Reed, D.; Lucas, M.; Warren, S.; Elgundi, Z.; Pinese, M.; Kalna, G.; Roden, D.; Samuel, M.; Zaratzian, A.; Grey, S.; Da Silva, A.; Leung, W.; Johns, A.; et al.
2016Caffeine toxicity in forensic practice: possible effects and under-appreciated sourcesMusgrave, I.; Farrington, R.; Hoban, C.; Byard, R.